|
◇Ildong Pharmaceutical Surges on Subsidiary Re-merger Issue
According to KG Zeroin's MP DOCTOR (formerly Market Point), Ildong Pharmaceutical's stock price skyrocketed on the NextTrade (NXT) market that day. While Ildong Pharmaceutical closed the regular trading session down 1.48% at 26,700 won, it later surged 15.87% to 31,400 won during NextTrade hours.
Ildong Pharmaceutical's stock price increase is analyzed to be driven by the decision to absorb and merge its subsidiary, Yunobia. Ildong Pharmaceutical announced in a regulatory filing that its board of directors resolved to absorb its wholly owned (100%) subsidiary, Yunobia.
The merger ratio is 1:0, meaning it is a merger without the issuance of new shares. The merger agreement date is the 15th of this month, and the merger date is June 16th. As it is conducted as a small-scale merger, it will be finalized with board approval without a general shareholders' meeting, and appraisal rights will not be granted to Ildong Pharmaceutical shareholders.
Yunobia is a subsidiary specializing in new drug R&D, established by Ildong Pharmaceutical in November 2023 through a physical spin off of its R&D division, with a workforce of fewer than 30 employees. Its total equity stands at a deficit of 14.7 billion won, indicating complete capital impairment.
The reason Ildong Pharmaceutical is re-merging the subsidiary it spun off two years ago is interpreted as a move to improve management efficiency by effectively combining human and material resources and internalizing its new drug R&D pipeline. The decision also appears to align with industry and regulatory conditions, such as the implementation of the revised drug pricing system.
Last year, Ildong Pharmaceutical successfully derived top-line data for the Phase 1 clinical trial of its ‘GLP-1RA’ obesity treatment (ID110521156) through Yunobia. It also achieved significant milestones in new drug R&D, including the entry of its P-CAB peptic ulcer treatment (Padoprazan) into Phase 3 clinical trials.
Utilizing the merger with Yunobia as a stepping stone, Ildong Pharmaceutical plans to accelerate the technology export of key pipelines, such as the GLP-1RA obesity treatment and P-CAB peptic ulcer treatment.
Furthermore, the group plans to realign its R&D system and strategy to strengthen its new drug R&D capabilities and business momentum, while building an organic collaborative system among relevant organizations.
An Ildong Pharmaceutical official stated "Since the government's stance is to provide preferential treatment in the drug pricing system based on the proportion of R&D investment, we determined that we needed to further increase our R&D proportion to meet these criteria." The official added "As Yunobia was already a 100% subsidiary, nothing significant will change even with the re merger.“
◇Spotlight on Stem Cell Developers Medipost and Kangstem Biotech
On this day, Medipost's stock price closed at 23,900 won, up 18.02% from the previous day. Kangstem Biotech closed at 4,050 won, an increase of 12.50%. The stock price surges of these two companies are attributed to growing expectations surrounding the proposed amendment to the Advanced Regenerative Medicine Act, which could ease regulations on stem cell therapies and accelerate commercialization.
According to industry sources, a proposed amendment to the Advanced Regenerative Medicine Act has recently been introduced in the National Assembly. The amendment includes provisions to expand the scope of utilizing embryonic stem cell-based therapies. Under the existing law, hospitals could only manufacture treatments using cells collected directly from patients. However, following this revision, it will be possible to produce treatments by receiving cell lines secured from external institutions.
Even with Good Manufacturing Practice (GMP) facilities, obtaining approval for cell processing facilities was highly restrictive, but these regulations will now be relaxed. This is expected to enable the mass production and standardization of stem cell therapies, ultimately accelerating product commercialization and market entry.
In particular, the stock surges appear to reflect investor expectations, as Medipost and Kangstem Biotech are scheduled to announce crucial data in the second and third quarters.
First, attention is focused on Medipost's core product, the degenerative knee osteoarthritis treatment 'Cartistem,' specifically regarding the results of its Phase 3 clinical trials in Japan and the initiation of Phase 3 trials in the US.
The data from the Japanese Phase 3 clinical trial, which concluded last month, is scheduled to be announced within the second quarter. The primary endpoint is symptom improvement at 52 weeks post surgery, and the secondary endpoint is the degree of structural cartilage improvement.
Given that the effect duration of the control group's hyaluronic acid injection is only about six months, the trial is considered relatively less difficult compared to Korea, indicating a high probability of success. Furthermore, the US Phase 3 clinical trial may commence within this month.
A Medipost official stated, "There is no particularly new information other than what is already known regarding the announcement of the Japanese Phase 3 results and entry into the US clinical trials. It seems expectations for the research outcomes are beginning to build.“
Kangstem Biotech completed patient dosing for the Phase 2a clinical trial of its knee osteoarthritis treatment 'Furestem-OA Kit (OSCA)' in November of last year and is currently organizing the data. The top-line data for OSCA's Phase 2a trial is scheduled for release in July.
Kangstem Biotech is also gaining attention for its 'organoids.' Organoids are drawing significant interest both domestically and internationally in tandem with the US Food and Drug Administration's (FDA) policy to reduce non clinical animal testing. In line with the recent trend Kangstem Biotech has reorganized its single organoid research department into two teams and reinforced its personnel.
A Kangstem Biotech official commented "Rather than a temporary stock price increase solely due to the proposal of the legal amendment it seems a steady upward trend is continuing alongside a generally positive market atmosphere."
Copyright ⓒ 이데일리 무단 전재 및 재배포 금지
본 콘텐츠는 뉴스픽 파트너스에서 공유된 콘텐츠입니다.
다음 내용이 궁금하다면?
광고 보고 계속 읽기
원치 않을 경우 뒤로가기를 눌러주세요
